A Study of a Novel Multi-Wavelength Laser for Tattoo Removal
Study Details
Study Description
Brief Summary
Single center study to evaluate the safety and efficacy of an investigational version of the Cutera enlightenTM laser that offers multiple wavelengths for tattoo removal.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
A single-center prospective, open-label, uncontrolled pilot study to evaluate the safety and efficacy of an investigational version of the Cutera enlightenTM laser that offers multiple wavelengths for tattoo removal.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Treatment Treatment with investigational Cutera enlighten laser for tattoo removal |
Device: enLighten Laser
Laser for tattoo removal
|
Outcome Measures
Primary Outcome Measures
- Tattoo clearing as rated by Investigator [6 weeks post-final treatment]
Degree of tattoo clearing at 6 weeks post-final treatment as assessed by the Investigator (Physician's Global Assessment of Improvement).
Secondary Outcome Measures
- Tattoo clearing as rated by Subject [6 weeks post-final treatment]
Degree of tattoo clearing at 6 weeks post-final treatment as assessed by the subject (Subject's Global Assessment of Improvement).
- Subject satisfaction Questionnaire [6 weeks post-final treatment]
Subject satisfaction levels at 6 weeks post-final treatment using Subject Satisfaction Assessment Scale.
Other Outcome Measures
- Tattoo clearing as rated by Blinded Evaluator [6 weeks post-final treatment]
Degree of tattoo clearing at 6 weeks post-final treatment as assessed by independent blinded reviewers (Global Assessment of Improvement).
- Adverse Device Effects [through study completion, an average of 1 year]
Number and severity of adverse device effects during the study period
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Female or Male, 18 to 65 years of age (inclusive).
-
Fitzpatrick Skin Type I - VI.
-
Target tattoo contains single or multi-color ink.
-
Subject must be able to read, understand and sign the Informed Consent Form.
-
Must be willing and able to adhere to the treatment and follow-up schedule and post-treatment care instructions.
-
Wiling to cover tattoos with a bandage or clothing; and/or have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the treated area starting 2 to 4 weeks before the treatment and/or every day for the duration of the study, including the follow-up period.
-
Willing to have digital photographs taken of the treatment area and agree to use of photographs for presentation, educational or marketing purposes.
-
Agree to not undergo any other procedure(s) for tattoo removal during the study (as applicable).
-
Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study, and no plans to become pregnant for the duration of the study.
Exclusion Criteria:
-
Participation in a clinical trial of a drug or another device in the target area during the study.
-
Target tattoo contains only black ink.
-
History of allergic reaction to pigments following tattooing.
-
History of allergy to local anesthetics.
-
History of allergy to topical antibiotics.
-
History of malignant tumors in the target area.
-
Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, scars, large moles.
-
Pregnant and/or breastfeeding.
-
Having an infection, dermatitis or a rash in the treatment area.
-
Significant concurrent illness, such as diabetes mellitus or cardiovascular disease, e.g., uncontrolled hypertension.
-
Suffering from coagulation disorders or taking prescription anticoagulation medications.
-
History of keloid scarring, hypertrophic scarring or of abnormal wound healing.
-
History of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications.
-
History of vitiligo, eczema, or psoriasis.
-
History of connective tissue disease, such as systemic lupus erythematosus or scleroderma.
-
History of seizure disorders due to light.
-
Any use of medication that is known to increase sensitivity to light according to Investigator's discretion.
-
History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen
-
History of radiation to the treatment area or undergoing systemic chemotherapy for the treatment of cancer.
-
History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation.
-
Systemic use of corticosteroid or isotretinoin within 6 months of study participation.
-
Anytime in life, having have used gold therapy (gold salts) for disorders such as rheumatologic disease or lupus.
-
Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study.
-
Current smoker or history of smoking within 6 months of study participation.
-
As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Connecticut Skin Institute | Stamford | Connecticut | United States | 06905 |
Sponsors and Collaborators
- Cutera Inc.
Investigators
- Principal Investigator: Omar Ibrahimi, MD, Connecticut Skin Institute
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- C-16-EN14